Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies

Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies

During the SARS-CoV-2 vaccination campaign, people with CF (pwCF) were considered a clinically vulnerable population. However, data on the immunogenicity of anti-SARS-CoV-2 vaccines in pwCF are lacking. We conducted a prospective study enrolling all patients aged > 12 and who were followed-up in...

Full description

Bibliographic Details
Main Authors: Gianfranco Alicandro, Valeria Daccò, Lisa Cariani, Chiara Rosazza, Calogero Sathya Sciarrabba, Federica Ferraro, Chiara Lanfranchi, Paola Medino, Daniela Girelli, Carla Colombo
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Biomedicines
Subjects:
cystic fibrosis
SARS-CoV-2
COVID-19
vaccine
antibody response
humoral response
Online Access:https://www.mdpi.com/2227-9059/10/8/1998

Internet

https://www.mdpi.com/2227-9059/10/8/1998

Similar Items